Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DM001 |
Synonyms | |
Therapy Description |
DM001 is a bispecific antibody-drug conjugate (ADC) targeting TROP2 and EGFR, which potentially inhibits cell cycle progression and induces apoptosis in tumor cells, and decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): LB215). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DM001 | DM 001|DM-001 | EGFR Antibody 60 TROP2 Antibody 13 | DM001 is a bispecific antibody-drug conjugate (ADC) targeting TROP2 and EGFR, which potentially inhibits cell cycle progression and induces apoptosis in tumor cells, and decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): LB215). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06475937 | Phase I | DM001 | A Study of DM001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |